Results 181 to 190 of about 99,253,553 (299)

Real‐world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24‐week prospective multicenter observational study in Korea

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To evaluate the real‐world effectiveness and safety of enavogliflozin as a single‐pill formulation (Enavo group; enavogliflozin 0.3 mg) or fixed‐dose combination with metformin (EnavoMet group; enavogliflozin 0.3 mg/metformin 1000 mg) in patients with type 2 diabetes (T2DM) in Korean primary care.
Hyunji Sang, Yeongtaek Hwang, Selin Woo, Soo Jin Yun, Meehoh Kim, Ho Geol Woo, Joo Young Kim, Dong Keon Yon, Sang Youl Rhee   +8 more
wiley   +1 more source

DPP-4 inhibitor linagliptin modulates myocardial metabolism in a model of coronary artery disease. [PDF]

JTCVS Open
Muir KC, Harris DD, Stone C, Kanuparthy M, Hamze J, Sellke FW.   +5 more
europepmc   +1 more source

The low fasting serum C‐peptide level was associated with reduced sural nerve action potential amplitudes: A cross‐sectional study of Japanese type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
Low fasting serum C‐peptide levels were independently associated with abnormal sural nerve action potential amplitude measured by DPNCheck® in patients with type 2 diabetes. Fasting serum C‐peptide may serve as a clinically relevant marker for diabetic polyneuropathy. ABSTRACT Aims/Introduction The association between the fasting serum C‐peptide levels
Taichi Muramatsu, Kaori Inoue‐Yamamoto, Daisuke Yamamuro, Akifumi Kushiyama   +3 more
wiley   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer. [PDF]

Cancer Res Commun, 2021
Saito A, Kitayama J, Horie H, Koinuma K, Kawashima R, Ohzawa H, Yamaguchi H, Kawahira H, Mimura T, Lefor AK, Sata N.   +10 more
europepmc   +1 more source

Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with MASLD and type 2 diabetes: A single‐arm pre–post study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is common in subjects with type 2 diabetes mellitus (T2DM), being linked to a higher risk for the development of liver‐related and cardiovascular diseases.
Mobina Shieh, Davood Dalil, Alireza Arefzadeh, Maryam Shiehmorteza   +3 more
wiley   +1 more source

Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine. [PDF]

Case Rep Gastrointest Med
Nasser A, Ladadweh H, Madia R, Dalashi A, Wahdan A, Alawi A.   +5 more
europepmc   +1 more source

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. [PDF]

Lancet Diabetes Endocrinol, 2023
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J, DINAMO Study Group.   +8 more
europepmc   +1 more source

Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Bullous pemphigoid prevalence in Germany has risen substantially, particularly among older adults, and is associated with increased comorbidity burden, threefold higher mortality and markedly greater healthcare utilization and costs. These findings highlight a growing clinical and economic burden in ageing populations requiring improved management ...
Anna C. Meyer, Inka Albrecht, Lena Hasemann, Jana Diekmannshemke, Oliver Damm, Daniel Gensorowsky, Julian Witte, Sven R. Quist, Ulrike Raap, Enno Schmidt   +9 more
wiley   +1 more source

MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Santos AS, Bando SY, Correa Giannella MLC, da Silva MER.   +3 more
europepmc   +1 more source